Recursion Pharmaceuticals

RXRX

Market cap $2.96B

Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Recursion Pharmaceuticals (RXRX 1.84%), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at all) as it does now on Wall Street. Although things have changed on that front, Recursion has not benefited from the skyrocketing interest in AI companies.

The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.

While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don't build foundation models or design AI chips -- they apply existing AI technology to transform inefficient industries and outdated processes.

BigBear.ai (BBAI -6.00%) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Mid-cap Biotech Equity Research here at the firm.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Call Participants Andrew Pucher Presentation Andrew Pucher Welcome to this afternoon session with Recursion. My name is Andrew Pucher.